scispace - formally typeset
P

Peggy S. Eis

Researcher at Hoffmann-La Roche

Publications -  44
Citations -  4406

Peggy S. Eis is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Comparative genomic hybridization & Cleavage (embryo). The author has an hindex of 21, co-authored 43 publications receiving 4228 citations. Previous affiliations of Peggy S. Eis include University of Wisconsin-Madison & French Institute of Health and Medical Research.

Papers
More filters
Patent

Methods and compositions for diagnosing, prognosing, and treating neurological conditions

TL;DR: In this paper, the authors provide methods and materials related to genetic variations of neurological disorders, such as Parkinson's disease, to assess susceptibility of individuals to developing Parkinson's diseases, using genetic information.
Journal ArticleDOI

Multiplexed gene expression analysis using the invader RNA assay with MALDI-TOF mass spectrometry detection.

TL;DR: Simultaneous analysis of human cytokine in vitro transcripts IL-1beta, TNF-alpha, and IL-6, with GAPDH as a reference standard, was used as a model system to demonstrate this novel method of gene expression analysis.
Journal ArticleDOI

Quantification of alternatively spliced FGFR2 RNAs using the RNA invasive cleavage assay

TL;DR: The RNA invasive cleavage assay was used to demonstrate a novel function for the regulatory element IAS2 in repressing exon IIIc inclusion, and it was shown here that purification of RNA is not necessary for the invasive Cleavage assay, because crude cell lysates could be used to accurately measure alternative transcripts.
Patent

RNA detection enzymes

TL;DR: In this paper, the cleavage agents and polymerases are used for the detection and characterization of nucleic acid sequences and variations in nucleic amino acid sequences, and the 5' nuclease activity of a variety of enzymes is used to cleave a target-dependent cleavage structure, thereby indicating the presence of specific nucleic acids sequences or specific variations thereof.
Journal ArticleDOI

Germline Genetic Risk Variants for Progressive Multifocal Leukoencephalopathy

TL;DR: A PML risk prediction test would have clinical utility in all at risk patient groups but would be particularly beneficial in patients considering therapy with immunosuppressant agents known to cause PML, such as natalizumab, rituximab, and others.